Communiqués China SXT Pharmaceuticals, Inc.

Actions

SXTC

VGG2161P1650

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 31/07/2026			Varia. 5j.	Varia. 1 janv.
0,0618 ^USD	-15,39%		-3,13%	-99,97%

30/07	Les plus fortes hausses en pré-séance	MT
28/07	Les plus fortes baisses en avant-bourse	MT

Communiqués

24/07	Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)	AQ
23/07	China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering	AQ
01/07	China SXT Pharmaceuticals : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)	PU
24/03	China SXT Pharmaceuticals, Inc. Announces Share Re-classification	AQ
30/01	China SXT Pharmaceuticals, Inc. Announces Share Consolidation	AQ
15/01	CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN	AQ
13/01	Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)	AQ
09/01	China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering	AQ
08/01	CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT	AQ
17/03/25	China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency	AQ
21/02/25	China SXT Pharmaceuticals, Inc. Announces Share Consolidation	AQ
15/10/24	China SXT Pharmaceuticals : Changes in Registrant’s Certifying Accountant Form 6 K	PU
07/10/24	China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency	AQ
14/05/24	China SXT Pharmaceuticals : May 2024 Note - Form 6-K	PU
05/04/24	China SXT Pharmaceuticals : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Form 6-K	PU
26/10/23	China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq’s Minimum Bid Price Rule	AQ
04/10/23	China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split	AQ
10/05/23	China SXT Pharmaceuticals, Inc. Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule	AQ
23/03/23	China SXT Pharmaceuticals : Purchase Agreement - Form 6-K	PU
01/03/23	China SXT Pharmaceuticals : Securities Purchase Agreement - Form 6-K	PU
25/02/23	China SXT Pharmaceuticals : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Form 6-K	PU
23/12/22	China SXT Pharmaceuticals : Securities Purchase Agreement - Form 6-K	PU
07/11/22	China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency	AQ
12/10/22	China SXT Pharmaceuticals : Securities Purchase Agreement - Form 6-K	PU
18/05/22	China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split	GL